标题/作者	年份
Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection JM Dan, J Mateus, Y Kato, KM Hastie, ED Yu, CE Faliti, A Grifoni, ... Science 371 (6529), eabf4063	2021
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial PM Folegatti, KJ Ewer, PK Aley, B Angus, S Becker, ... The Lancet 396 (10249), 467-478	2020
SARS-CoV-2 vaccines in development F Krammer Nature 586 (7830), 516-527	2020
SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls N Le Bert, AT Tan, K Kunasegaran, CYL Tham, M Hafezi, A Chia, ... Nature 584 (7821), 457-462	2020
Convergent antibody responses to SARS-CoV-2 in convalescent individuals DF Robbiani, C Gaebler, F Muecksch, JCC Lorenzi, Z Wang, A Cho, ... Nature 584 (7821), 437-442	2020
Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19 T Sekine, A Perez-Potti, O Rivera-Ballesteros, K Strålin, JB Gorin, ... Cell 183 (1), 158-168. e14	2020
Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity CR Moderbacher, SI Ramirez, JM Dan, A Grifoni, KM Hastie, D Weiskopf, ... Cell 183 (4), 996-1012. e19	2020
Evolution of antibody immunity to SARS-CoV-2 C Gaebler, Z Wang, JCC Lorenzi, F Muecksch, S Finkin, M Tokuyama, ... Nature 591 (7851), 639-644	2021
Adaptive immunity to SARS-CoV-2 and COVID-19 A Sette, S Crotty Cell 184 (4), 861-880	2021
mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants Z Wang, F Schmidt, Y Weisblum, F Muecksch, CO Barnes, S Finkin, ... Nature 592 (7855), 616-622	2021
Deep immune profiling of COVID-19 patients reveals distinct immunotypes with therapeutic implications D Mathew, JR Giles, AE Baxter, DA Oldridge, AR Greenplate, JE Wu, ... Science 369 (6508), eabc8511	2020
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial FC Zhu, XH Guan, YH Li, JY Huang, T Jiang, LH Hou, JX Li, BF Yang, ... The Lancet 396 (10249), 479-488	2020
Individuals with obesity and COVID‐19: a global perspective on the epidemiology and biological relationships BM Popkin, S Du, WD Green, MA Beck, T Algaith, CH Herbst, RF Alsukait, ... Obesity reviews 21 (11), e13128	2020
Mapping neutralizing and immunodominant sites on the SARS-CoV-2 spike receptor-binding domain by structure-guided high-resolution serology L Piccoli, YJ Park, MA Tortorici, N Czudnochowski, AC Walls, ... Cell 183 (4), 1024-1042. e21	2020
Mechanisms of SARS-CoV-2 transmission and pathogenesis AG Harrison, T Lin, P Wang Trends in immunology 41 (12), 1100-1115	2020
Severe COVID-19 is marked by a dysregulated myeloid cell compartment J Schulte-Schrepping, N Reusch, D Paclik, K Baßler, S Schlickeiser, ... Cell 182 (6), 1419-1440. e23	2020
Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19 Y Peng, AJ Mentzer, G Liu, X Yao, Z Yin, D Dong, W Dejnirattisai, ... Nature immunology 21 (11), 1336-1345	2020
Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed humans J Mateus, A Grifoni, A Tarke, J Sidney, SI Ramirez, JM Dan, ZC Burger, ... Science 370 (6512), 89-94	2020
Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates KS Corbett, B Flynn, KE Foulds, JR Francica, S Boyoglu-Barnum, ... New England Journal of Medicine 383 (16), 1544-1555	2020
Immunological considerations for COVID-19 vaccine strategies M Jeyanathan, S Afkhami, F Smaill, MS Miller, BD Lichty, Z Xing Nature Reviews Immunology 20 (10), 615-632	2020

1 - 20

计算机程序会自动估算并确定日期和引用次数。